The amino-terminal extracellular domain of the MCP-1 receptor, but not the RANTES/MIP-1alpha receptor, confers chemokine selectivity. Evidence for a two-step mechanism for MCP-1 receptor activation.
about
Role of the first extracellular loop in the functional activation of CCR2. The first extracellular loop contains distinct domains necessary for both agonist binding and transmembrane signalingIdentification of the binding site for a novel class of CCR2b chemokine receptor antagonists: binding to a common chemokine receptor motif within the helical bundleOrganization and differential expression of the human monocyte chemoattractant protein 1 receptor gene. Evidence for the role of the carboxyl-terminal tail in receptor traffickingCloning and characterization of a novel murine beta chemokine receptor, D6. Comparison to three other related macrophage inflammatory protein-1alpha receptors, CCR-1, CCR-3, and CCR-5The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactionsInvolvement of CC chemokine ligand 18 (CCL18) in normal and pathological processesMurine monocyte chemoattractant protein (MCP)-5: a novel CC chemokine that is a structural and functional homologue of human MCP-1Biased and g protein-independent signaling of chemokine receptorsChemokine receptor CXCR2: physiology regulator and neuroinflammation controller?CXCR2: a target for pancreatic cancer treatment?A tethered agonist within the ectodomain activates the adhesion G protein-coupled receptors GPR126 and GPR133Identification of CCR6, the specific receptor for a novel lymphocyte-directed CC chemokine LARCThe T cell-directed CC chemokine TARC is a highly specific biological ligand for CC chemokine receptor 4A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5Inhibition of the angiogenesis by the MCP-1 (monocyte chemoattractant protein-1) binding peptide.A small molecule antagonist of chemokine receptors CCR1 and CCR3. Potent inhibition of eosinophil function and CCR3-mediated HIV-1 entry.Small molecule receptor agonists and antagonists of CCR3 provide insight into mechanisms of chemokine receptor activation.Identification of CXCR4 domains that support coreceptor and chemokine receptor functionsSmall molecule chemokine mimetics suggest a molecular basis for the observation that CXCL10 and CXCL11 are allosteric ligands of CXCR3Role of CCR2 in inflammatory conditions of the central nervous system.The amino-terminal domain of CCR2 is both necessary and sufficient for high affinity binding of monocyte chemoattractant protein 1. Receptor activation by a pseudo-tethered ligand.Solution structure and basis for functional activity of stromal cell-derived factor-1; dissociation of CXCR4 activation from binding and inhibition of HIV-1.Aberrant proliferation in CXCR7+ endothelial cells via degradation of the retinoblastoma protein.Chemokine and chemokine receptor structure and interactions: implications for therapeutic strategies.The CCL2 chemokine is a negative regulator of autophagy and necrosis in luminal B breast cancer cellsTwo distinct CCR5 domains can mediate coreceptor usage by human immunodeficiency virus type 1.Visualization of chemokine binding sites on human brain microvesselsSialylated O-glycans and sulfated tyrosines in the NH2-terminal domain of CC chemokine receptor 5 contribute to high affinity binding of chemokinesStructural basis of chemokine receptor function--a model for binding affinity and ligand selectivitySoluble mimics of a chemokine receptor: chemokine binding by receptor elements juxtaposed on a soluble scaffoldThe differential sensitivity of human and rhesus macaque CCR5 to small-molecule inhibitors of human immunodeficiency virus type 1 entry is explained by a single amino acid difference and suggests a mechanism of action for these inhibitorsChemokine receptors in epithelial ovarian cancerHuman Cytomegalovirus US28: a functionally selective chemokine binding receptor.US28, a Virally-Encoded GPCR as an Antiviral Target for Human Cytomegalovirus Infection.Targeted gene silencing of CCL2 inhibits triple negative breast cancer progression by blocking cancer stem cell renewal and M2 macrophage recruitment.Pharmacological modulation of chemokine receptor function.Chemokines: established and novel targets in atherosclerosis.Role of chemokine CCL2 and its receptor CCR2 in neurodegenerative diseases.Lysophosphatidylcholine phosphorylates CREB and activates the jun2TRE site of c-jun promoter in vascular endothelial cells.Tyrosine sulfation is prevalent in human chemokine receptors important in lung disease.
P2860
Q22010723-C99B9650-B48D-4D5E-B4CF-ADCF8AC854B4Q22253922-59B752D2-88FA-4889-8802-2241BEAC0497Q24313016-DAC39869-F172-4169-9C2F-482AC58646D3Q24318708-549FF474-E7C4-4F94-8C09-95A84E60F21AQ24564834-AC7404A8-D8AE-4CE2-88DC-A214673D553BQ24647107-BC5324C3-FF3B-4D35-BB2A-0C4A2427A240Q24670294-6D85BC87-C464-478E-BCE0-76FD9BC662F6Q26823970-57DABD13-5F2F-44CD-BCC2-00B46629F41DQ27007078-3BAF2BEC-1219-4C9C-B118-E37122F8828FQ27021588-3F4F6A4D-064E-4911-B377-EA6937D66FDCQ28119003-FDF6D8A8-9BDD-4CEB-90B1-AC896927F2EBQ28239561-312317A8-8361-4EC2-AFDD-79B67756753EQ28239606-5B856FB0-1581-49E8-8199-0C19072DA96EQ28344177-7ED785A9-2D27-49CC-AC62-69C2DDBEF55BQ31152491-05CD71B7-FA64-4C58-B40F-58294697B18AQ31395542-6850A6B7-B165-4B5D-ADBC-18F2187B1F0FQ33291059-960DA290-395A-4E1D-B1A9-32A2EC1BE8EAQ33643223-283B90BA-237B-4E99-9D70-D95CE311C635Q34012132-C4B5EB4B-2A2D-4076-B81A-47DCF1A09841Q34153471-EB5807C4-3391-4F12-8563-717C2E2EB47BQ34438280-0B797EA1-8AAB-44F6-B538-E45B1CECF373Q34447967-C9412505-3656-4D76-A185-9BF7CBBFB05EQ34874678-F7B7875E-DAFE-4EAA-AF6E-453E232011F2Q35528569-5ED2C364-D31B-4C5B-91EB-4905DF1ABD73Q35684572-91A8C06D-85BB-46B8-B46B-9269F4C9CAA4Q35890885-765222E4-30B0-47F3-90AE-4E0B78052EE9Q36256452-2A663266-1388-4199-B130-5FB081E9C84FQ36369644-355D7DD2-32C9-4C77-99E2-E4557407A105Q36616071-C49E1454-2ED4-4514-A2B6-A13768AC26BFQ36631409-87467EA5-CF09-4F91-8D87-1444BB96E0B0Q37092774-4FC4906E-7418-424D-A18C-DA78DD97270DQ37535454-D01BBDE4-EB9E-4F51-82B1-535BDA31F6B0Q37548510-493A9D57-1090-4917-86B6-D07A9C6EB188Q37551927-D3070FD8-32B9-40A1-8A5C-FEBF5FE0079BQ37580230-F8D46B46-7396-4632-8E0B-380CC13E30B4Q37893687-89B4A4EA-116B-4F2A-94EA-E1785B839848Q37950973-BD18AEB1-BA7E-4B8E-964B-6DDA1DF5F761Q38114832-A97F62E9-E9A5-40FB-995E-70121529CFC9Q38320971-29F84E75-2CB7-41D4-88C9-5F1E53448B8CQ38620316-191CF4F9-0038-4B39-BB35-450E0436FD94
P2860
The amino-terminal extracellular domain of the MCP-1 receptor, but not the RANTES/MIP-1alpha receptor, confers chemokine selectivity. Evidence for a two-step mechanism for MCP-1 receptor activation.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
The amino-terminal extracellul ...... for MCP-1 receptor activation.
@en
type
label
The amino-terminal extracellul ...... for MCP-1 receptor activation.
@en
prefLabel
The amino-terminal extracellul ...... for MCP-1 receptor activation.
@en
P2860
P356
P1476
The amino-terminal extracellul ...... for MCP-1 receptor activation.
@en
P2093
Monteclaro FS
P2860
P304
19084-19092
P356
10.1074/JBC.271.32.19084
P407
P577
1996-08-01T00:00:00Z